Olema Oncology (OLMA) jumps here with an unusual buy of 3100 December $30 calls for $4. OLMA is a $1B Biotech discovering therapies for women’s cancers. Olema’s lead product OP-1250 has the potential to emerge as a backbone therapy for breast cancer. Peak sales for OP-1250 could be $3B to $5B or higher according to Jefferies. Approval is likely a long way off with 2027 estimated. OLMA has a presentation of preliminary Phase 1/2 dose-escalation data for OP-1250 in patients with metastatic, ER+ / HER2- breast cancer planned for Q4 2021